Mason Street Advisors’s Puma Biotechnology PBYI Stock Holding History

Mason Street Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-18,015	Closed	-$3.41M	–	1676
2014 Q4	$3.41M	Hold	18,015	–	–	0.02%	714
2014 Q3	$4.3M	Sell	18,015 -7,000	-28%	-$1.44M	0.03%	571
2014 Q2	$1.65M	Hold	25,015	–	–	0.01%	1034
2014 Q1	$2.6M	Sell	25,015 -1,150	-4%	-$135K	0.02%	821
2013 Q4	$2.71M	Sell	26,165 -9,635	-27%	-$566K	0.02%	785
2013 Q3	$1.92M	Buy	+35,800	New	+$1.93M	0.02%	731

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Mason Street Advisors's PBYI Position: Q1 2015 in Review

Mason Street Advisors sold out of Puma Biotechnology (PBYI) in Q1 2015, closing a stake of 18,015 shares — an estimated $3.41M sold.

Mason Street Advisors first reported a position in PBYI in Q3 2013 and held it in 6 quarters. The position peaked at $4.3M in Q3 2014. 199 funds tracked by Wall St. Rank hold PBYI as of Q1 2015.

Mason Street Advisors reported no remaining Puma Biotechnology position as of Q1 2015 after selling out during the quarter.
Mason Street Advisors sold 18,015 Puma Biotechnology shares in Q1 2015, an estimated $3.41M.
Mason Street Advisors first reported a position in Puma Biotechnology in Q3 2013 and held it in 6 quarters.
Mason Street Advisors's Puma Biotechnology position peaked at $4.3M in Q3 2014.
199 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2015.

Based on Mason Street Advisors's 13F filing for Q1 2015, filed 15 May 2015.